CPMG Inc

Q1 2018 13F Holdings Report, Restatement, Stock Holdings

Signature - Title
John E. Bateman - Chief Operating Officer
Location
Dallas, TX
Holdings as of
31 Mar 2018
Value $
$142,543,000
Num holdings
15
Filing time
02 Oct 2018, 16:17:11 UTC
Form type
13F-HR/A-1 - Restatement
Description
All US holdings of this investor are reported in this report. Top holdings included RETA, KGC, KL, IAG, and GSS.
Previous filing
Q4 2017 - 02 Oct 2018
Next filing
Q2 2018 - 02 Oct 2018
SEC
View on sec.gov
Options Holdings
Showing stock holdings, see here for options holdings
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2018 Q1 - Restatement compared to 2017 Q4 - Restatement by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John E. Bateman Chief Operating Officer Dallas, Texas 02 Oct 2018

This Amendment Number 1 is being filed to restate the position information in Reata Pharmaceuticals, Inc. ("Reata"). The Form 13F-HR filed on May 15, 2018 inadvertently reported the position information for Reata as the total of Class A and Class B shares over which CPMG, Inc. ("CPMG") had investment discretion as of March 31, 2018. This Amendment Number 1 includes only the reportable 2,912,523 Class A shares over which CPMG had investment discretion as of March 31, 2018. This Amendment Number 1 does not include the 1,692,857 Class B shares of Reata over which CPMG had investment discretion as of March 31, 2018 because such Class B shares were not included in the relevant quarter's Official List of Section 13(f) Securities, and thus should be excluded.